Ticker Details
BioMarin Pharmaceutical Inc. Biomarin Pharmaceutical Inc is on rare-disease therapies. It develops and commercializes pharmaceuticals for serious diseases and medical conditions.
IPO Date:	August 1, 1999
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$11.59B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.95 | 1.76%
Avg Daily Range (30 D):	$1.04 | 1.87%
Avg Daily Range (90 D):	$0.88 | 1.58%

Institutional Daily Volume
Avg Daily Volume:	1.23M
Avg Daily Volume (30 D):	1.6M
Avg Daily Volume (90 D):	1.57M

Trade Size
Avg Trade Size (Sh.):	101
Avg Trade Size (Sh.) (30 D):	58
Avg Trade Size (Sh.) (90 D):	58

Institutional Trades
Total Institutional Trades:	24,853
Avg Institutional Trade:	$3.66M
Avg Institutional Trade (30 D):	$6.53M
Avg Institutional Trade (90 D):	$5.46M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	5

Market Closing Trades
Avg Closing Trade:	$11.46M
Avg Closing Trade (30 D):	$25.11M
Avg Closing Trade (90 D):	$21.3M
Avg Closing Volume:	149.4K

News

May 26, 2026 @ 5:00 PM Duchenne Muscular Dystrophy Clinical Trial Pipelin... Source: Delveinsight

May 21, 2026 @ 6:11 PM BioMarin Reveals Dwarfism Study Data, Stock Soars Source: Vandana Singh

Apr 25, 2026 @ 3:13 PM CIBRA Capital Makes a Big Merger Arbitrage Bet On ... Source: Cory Renauer

Mar 20, 2026 @ 4:07 PM Biotech Stock Up 372% Gets Sold as New Pick Rises ... Source: Jonathan Ponciano

Mar 17, 2026 @ 12:00 AM This Investor Sold $104 Million of Nuvalent Stock ... Source: Jonathan Ponciano

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$1.4	$.55	$-.24
Diluted EPS	$1.37	$.54	$-.24
Revenue	$3.24B	$766.21M	$874.57M
Gross Profit	$2.48B	$571.21M	$598.86M
Net Income / Loss	$268.74M	$105.53M	$-46.57M
Operating Income / Loss	$315.23M	$129.64M	$-44.61M
Cost of Revenue	$760.88M	$195M	$275.71M
Net Cash Flow	$2.02B	$1.76B	$60.35M
PE Ratio